[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2012019054A3 - Expression of antibody or a fragment thereof in lactobacillus - Google Patents

Expression of antibody or a fragment thereof in lactobacillus Download PDF

Info

Publication number
WO2012019054A3
WO2012019054A3 PCT/US2011/046665 US2011046665W WO2012019054A3 WO 2012019054 A3 WO2012019054 A3 WO 2012019054A3 US 2011046665 W US2011046665 W US 2011046665W WO 2012019054 A3 WO2012019054 A3 WO 2012019054A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
lactobacillus
expression
microorganism
Prior art date
Application number
PCT/US2011/046665
Other languages
French (fr)
Other versions
WO2012019054A2 (en
Inventor
Lennart HAMMARSTRÖM
Harold Marcotte
Original Assignee
Hera Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hera Pharmaceuticals, Inc. filed Critical Hera Pharmaceuticals, Inc.
Publication of WO2012019054A2 publication Critical patent/WO2012019054A2/en
Publication of WO2012019054A3 publication Critical patent/WO2012019054A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Described herein are methods and compositions for expressing an antibody or a fragment thereof in a microorganism and use of the microorganism to treat or prevent a pathogenic infection in a mammal.
PCT/US2011/046665 2010-08-05 2011-08-04 Expression of antibody or a fragment thereof in lactobacillus WO2012019054A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1013215.7A GB2482535A (en) 2010-08-05 2010-08-05 Expression of antibody or a fragment thereof in lactobacillus
GB10/132,157 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012019054A2 WO2012019054A2 (en) 2012-02-09
WO2012019054A3 true WO2012019054A3 (en) 2014-03-20

Family

ID=42931266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046665 WO2012019054A2 (en) 2010-08-05 2011-08-04 Expression of antibody or a fragment thereof in lactobacillus

Country Status (2)

Country Link
GB (1) GB2482535A (en)
WO (1) WO2012019054A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150037953A (en) * 2012-07-13 2015-04-08 각코호진 데이쿄 헤이세이 다이가쿠 Anti-tumour agent, marker for tumour detection, and oral vaccine agent
CN113677798A (en) * 2019-02-05 2021-11-19 伊兰科美国公司 Probiotic composition and method of use
CN111004734A (en) * 2019-03-21 2020-04-14 江南大学 Lactobacillus rhamnosus capable of regulating and controlling relative abundance of acinetobacter in intestinal tract
CN110408559B (en) * 2019-07-05 2021-04-23 青岛农业大学 Streptomyces roseosporus and application thereof
CN112522164B (en) * 2020-12-25 2023-04-21 新疆农业科学院微生物应用研究所（中国新疆-亚美尼亚生物工程研究开发中心） Forest fruit branch decomposition microbial inoculum and preparation method and application thereof
CN114652741B (en) * 2022-01-19 2023-08-25 昆明野水生物科技有限公司 Composition and preparation for inhibiting HPV and application of composition and preparation
CN114874944B (en) * 2022-05-24 2023-04-18 西南大学 Lactobacillus Coli for controlling pepper bacterial soft rot and application thereof
CN115281316B (en) * 2022-06-24 2023-07-21 黄淮学院 Composite fermentation microbial inoculum for degrading mycotoxin in meat product and preparation method of high-digestibility fermented chicken jerky
CN115895967B (en) * 2022-12-01 2024-01-12 上海利康精准医疗技术有限公司 Lactobacillus rhamnosus for resisting human papillomavirus HPV and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134101A1 (en) * 2003-01-30 2006-06-22 Immun System I.M.S. Ab Use of avian antibodies
US20070071742A1 (en) * 1998-11-30 2007-03-29 Fang Fang Humanized antibodies
US20070092535A1 (en) * 1997-04-18 2007-04-26 Archimedes Development Limited Delivery of drugs to mucosal surfaces
US20090226418A1 (en) * 2005-08-19 2009-09-10 Leo Gerardus Frenken Food Products Comprising Probiotic Micro-Organisms and Antibodies
US20100080869A1 (en) * 2004-05-25 2010-04-01 Watson James B Live Bacteria product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747310A (en) * 1992-07-10 1998-05-05 Meiji Milk Products Co., Ltd. Gene integration into chromosomes of lactobacillus delbrueckii species and integrants thereof
WO2007047573A2 (en) * 2005-10-14 2007-04-26 The Johns Hopkins School Of Medicine Reduction and prevention of cell-associated hiv transepithelial migration, microbides and other formulations and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092535A1 (en) * 1997-04-18 2007-04-26 Archimedes Development Limited Delivery of drugs to mucosal surfaces
US20070071742A1 (en) * 1998-11-30 2007-03-29 Fang Fang Humanized antibodies
US20060134101A1 (en) * 2003-01-30 2006-06-22 Immun System I.M.S. Ab Use of avian antibodies
US20100080869A1 (en) * 2004-05-25 2010-04-01 Watson James B Live Bacteria product
US20090226418A1 (en) * 2005-08-19 2009-09-10 Leo Gerardus Frenken Food Products Comprising Probiotic Micro-Organisms and Antibodies

Also Published As

Publication number Publication date
GB2482535A (en) 2012-02-08
WO2012019054A2 (en) 2012-02-09
GB201013215D0 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
GB2482536B (en) Expression of antibody or a fragment thereof in lactobacillus
WO2012019054A3 (en) Expression of antibody or a fragment thereof in lactobacillus
WO2012048152A3 (en) Probiotic therapies for autism
CO6630182A2 (en) Microorganisms and methods for the biosynthesis of butadiene
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
CL2013001134A1 (en) Composition of frozen yogurt comprising non-replicating probiotic microorganisms.
WO2014145958A3 (en) Network-based microbial compositions and methods
MY153116A (en) Smac mimetic
WO2013155468A3 (en) Microbial strains and their use in animals
WO2012087962A3 (en) Anti-mesothelin antibodies and immunoconjugates
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2011139348A3 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2011113019A3 (en) Ctla4 proteins and their uses
NZ705008A (en) Novel modulators and methods of use
WO2013070615A8 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
PL2707010T3 (en) Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
EA201290623A1 (en) Lactobacilli with antioxidant action
MY161868A (en) Anti-bv8 antibodies and uses thereof
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CL2013001314A1 (en) Composition of yogurt of thick consistency that includes non-replicating probiotic microorganisms.
MX342226B (en) Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract.
WO2014150957A3 (en) Nitrite-degrading and tsna-degrading bacteria and methods of making and using
GB201102108D0 (en) Diagnostic method
HK1201041A1 (en) Bacterial strains expressing methylase genes and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815349

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11815349

Country of ref document: EP

Kind code of ref document: A2